The Latest

• 

  HHS announces sweeping reorganization, including cuts of 10K workers

  Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

  Pharma

• 

  Sponsored by Pfizer

  Harnessing the power of AI to detect ATTR-CM

  From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

  Research & Development

• 

  Rx-to-OTC rule gets pushed back — again

  A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.

  Pharma

• 

  Profile

  The industry heavyweight behind Novavax’s push to bounce back

  As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

  Commercialization

• 

  Biogen plots new global headquarters in Kendall Square

  The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

  Biotech

• 

  Lilly, Novo expand DTC reach of obesity meds after compound win

  The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

  Pharma

• 

  Biotechs emerging from stealth take aim at pharma’s prime targets

  The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

  Biotech

• 

  How pharma could feel the pain of a recession

  Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

  Leadership

• 

  Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

  The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

  Biotech

• 

  The key factors shaping China’s biopharma boom

  Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

  Biotech

• 

  Vaccine makers face mRNA backlash as states seek further restrictions

  A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

  Pharma

• 

  Q&A

  How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

  Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

  Biotech

• 

  Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

  Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

  Biotech

• 

  Q&A

  Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

  The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

  Biotech

• 

  Takeda’s $770M deal deepens Big Pharma’s omics push

  The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

  Pharma

• 

  Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

  HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

  Leadership

• 

  IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

  Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

  Biotech

• 

  The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

  Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

  Biotech

• 

  Pricing transparency is in the spotlight — and that could be good news for drugmakers

  An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

  Commercialization

• 

  What’s driving pharma’s layoffs in 2025

  Familiar foes in the industry have claimed a slew of jobs in recent months.

  Biotech

• 

  As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges

  Experts say cost and other barriers present challenges to returning to U.S. shores.

  Manufacturing

• 

  How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?

  With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.

  Leadership

• 

  The time is ripe for pharma M&A. Why are drugmakers holding out?

  The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

  Biotech

• 

  The top 3 impacts of Trump’s health data purge

  Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

  Patient

• 

  New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

  Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

  Biotech

• 

  With patent losses on the horizon, Amgen refocuses its business strategy

  The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

  Biotech